cervomed.com (CRVO) - Long-Term Liabilities to Capital

CervoMed Corporation - graphic logo of issuer CRVO

The ratio of long-term loans to equity reflects the debt load dynamics for CervoMed Inc. (CRVO), where the current level is 0.00. CervoMed Inc. (CRVO) is recognized as an innovator in the therapy of Lewy body dementia, restoring cognitive abilities to patients. The team consists of elite neurobiologists motivated by stock options and a lack of bureaucracy. Meanwhile, financial stability depends on the results of clinical trials, which necessitates strict liquidity control.

CervoMed, Inc. (CRVO): Long-Term Debt to Equity from 02/21/2024 to 11/01/2026
Original product of CervoMed

This indicator measures the proportion of long-term liabilities relative to the organization's equity. The ratio determines the degree of financial autonomy and the resilience of the balance sheet structure to external shocks. The dynamics of long-term debt to equity allow for the tracking of credit expansion or deleveraging strategies. For CervoMed Inc. (CRVO), this is critical due to the absence of current commercial revenue. High borrowing levels while funding clinical trials for dementia drugs could heighten insolvency risks.

Analysis of competing companies

Long-Term Debt to Capital Ratio BIIB (Biogen Inc)|Long-Term Debt to Capital NBIX|RGC - Long-Term Liabilities to Capital|Axsome Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acadia-pharm.com ACAD|XENE - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Catalyst Corp (CPRX)|DNLI (Denali Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio harmonybiosciences.com (HRMY)|Long-Term Debt to Capital BHVN|AMLX - Long-Term Liabilities to Capital|Long-Term Debt to Equity Trevi Pharma TRVI|Long-Term Debt to Capital Coefficient PRAX|AVXL: Long-Term Debt to Equity Ratio|CBLL: Long-Term Debt to Equity|Prothena Corp (PRTA) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Alector (ALEC)|Long-Term Debt to Equity Annexon Inc.|Long-Term Debt to Equity Ratio Omeros Corp. (OMER)|Long-Term Debt to Capital NGNE|ACIU - Long-Term Liabilities to Capital|Long-Term Debt to Capital VYGR (Voyager Therapeutics, Inc.)|NMRA: Long-Term Debt to Capital Ratio|SCLX: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient TVGN (Tevogen Bio Inc.)|ACOG: Long-Term Debt to Capital|CGTX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Inhibikase Therapeutics, Inc.|Long-Term Debt to Capital Ratio SAVA (Cassava Sciences Inc)|Long-Term Debt to Capital ASRT|Long-Term Debt to Equity Ratio coyatherapeutics.com COYA|Vistagen - Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital Ovid Therapeutics Inc (OVID)|Acumen Pharmaceuticals, Inc. - Long-Term Debt to Capital|Alterity Therapeutics (ATHE) - Long-Term Debt to Equity Ratio|clene.com (CLNN) - Long-Term Debt to Equity|PepGen - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio JUNS|Long-Term Debt to Equity RLMD|Long-Term Debt to Equity Annovis Bio (ANVS)|GRCE - Long-Term Liabilities to Capital|Long-Term Debt to Equity Firefly Neuroscience Inc AIFF|KLTO: Long-Term Debt to Capital Ratio|NeuroSense Therapeutics, Ltd. - Long-Term Debt to Capital|Long-Term Liabilities to Capital revivapharma.com|MTVA (metaviatx.com) - Long-Term Debt to Equity Ratio|NeurAxis Inc. (NRXS) - Long-Term Debt to Capital|Long-Term Debt to Equity Helius Medical Technologies, Inc.|PASG: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Neuphoria Therapeutics Inc. (NEUP)|NERV - Long-Term Liabilities to Capital|Long-Term Debt to Capital ATHA (Athira Pharma)|ADXN - Long-Term Debt to Equity Ratio|Alzamend - Long-Term Debt to Capital|Long-Term Liabilities to Capital Cyclerion Therapeutics|protagenic.com (PTIX) - Long-Term Debt to Equity|Pasithea Therapeutics Corp. - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio CRGT|Long-Term Debt to Equity ATXI|Long-Term Debt to Equity Brainstorm Cell Therapeutics, Inc. (BCLI)|CARA - Long-Term Liabilities to Capital|Long-Term Debt to Equity Chromocell Therapeutics CHRO|ELYM - Long-Term Debt to Equity Ratio|Intra-Cellular - Long-Term Debt to Capital|Long-Term Liabilities to Capital Longboard Pharmaceuticals Inc|MRNS: Long-Term Debt to Capital|Long-Term Debt to Capital Ratio NKGN|Long-Term Debt to Equity Ratio NRBO|SAGE: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital SNPX|Ratio of Long-Term Indebtedness to Capital Trevena Inc.|Long-Term Debt to Equity Vigil Neuroscience, Inc. VIGL|WENA: Long-Term Debt to Capital Ratio|Cerevel Therapeutics - Long-Term Debt to Capital